ISTH 2020 Congress

Hemophilia and Rare Bleeding Disorders

Theme Navigation

ISTH 2020 Congress
- Hemophilia and Rare Bleeding Disorders

Abstract Number: PB0972

“Best of Both Worlds”: Combination Treatment of Desmopressin and FVIII Concentrates in Hemophilia Patients Optimizes Therapy and Reduces Costs

L.G.R. Romano¹, L.M. Schütte¹, R.M. van Hest², K. Meijer³, B.A.P. Laros-van Gorkom⁴, L. Nieuwenhuizen⁵, J. Eikenboom⁶, F.C.J.I. Moenen⁷, N. Uitslager⁸, M. Coppens⁹, M.H. Cnossen¹⁰, K. Fijnvandraat^11,12, M.H.E. Driessens¹³, S. Polinder¹⁴, F.W.G. Leebeek¹, R.A.A. Mahtôt², M.J.H.A. Kruip¹

Abstract Number: PB1058

Case report: Inhibitor Improvement with Low Dose Immune Tolerance Induction (ITI) with rFVIIIFc and Emicizumab after Failed First Line Therapy with High Dose ITI

I. Wieland¹, K.-A. Lambeck¹, D. Stichel², A. Orlowski², C. Königs²

Abstract Number: PB0838

In vitro and in sillico Analysis of F9 Gene Missense Mutations at Exons 2 and 3 Causative of Severe Hemophilia B

L. Melendez Aranda^1,2, A.R. Jaloma Cruz², M.M.d.J. Romero Prado³

Abstract Number: PB0775

In vitro Correction of Thrombin Generation by Recombinant Porcine Factor VIII (rpFVIII) in Plasma Containing Anti-Factor VIII Inhibitory Antibodies

C. Négrier¹, J. Oldenburg², G. Kenet³, N. Tripkovic⁴, S.L. Meeks⁵

Abstract Number: PB0821

In vitro Effect of Concizumab on Protein C Activation and Antithrombin Activity

M. Kjalke, H. Heibroch Petersen, I. Hilden

Abstract Number: PB1041

3D Gait Analysis, Hemophilia Joint Health Score, Leg Muscle Laterality, and Biomarkers of Joint Damage: A Cross-sectional Comparative Assessment of Hemophilic Arthropathy

P. Putz¹, S. Durstberger², C. Kaufmann², M. Klinger², K. Widhalm², J. Rejtö³, C. Male⁴, I. Pabinger³

Abstract Number: PB1186

A Bypass Surgery with Congenital Factor 5 and Factor 8 Deficiency

V. Okan, H.H. Şahin, D.M. Akkurd

Abstract Number: PB0905

A Canadian, Multi-Center, Retrospective, Non-Interventional Study of Clinical Outcomes from Early Use of N9-GP Compared with Previous Treatment in Patients with Hemophilia B in a Real-World Setting

D. Matino¹, A. Iorio¹, A. Keepanasseril¹, F. Germini², A.C. Birkegård³, A. Caillaud⁴, M. Carcao⁵, J. Hews-Girard⁶, E. Iserman⁷, P. James⁸, A. Lee⁹, C. Phua¹⁰, H. Sun¹¹, J. Teitel¹², M.-C. Poon¹³

Abstract Number: PB0856

A Comparative Analysis of the Immune Response to Homologous Coagulation Factors V and VIII

M.L. Sauer¹, A.R. Wilhelm¹, R.J. Davidson¹, L.A. George^1,2, R.M. Camire^2,3

Abstract Number: PB1075

A Descriptive Study of Physical Activity and Fitness Level Profiles of Nigerians with Haemophila

H. Okoye¹, T. Nwagha¹, N. Chigbo², E. Anekwu³

Abstract Number: PB1196

A Digestive Hemorrhage Like No Other

Y. Cherif, S. Hamrouni, M. Mrouki, S. Derbel, F. Ben Dahmen, M. Abdallah

Abstract Number: PB0889

A French Multicentre Prospective, Non-Interventional Study (B-SURE) Evaluating Real-World Usage and Effectiveness of Recombinant Factor IX Fc Fusion Protein (rFIXFc) in People with Haemophilia B: Baseline Data

H. Chambost¹, B. Wibaut², A. Borel Derlon³, S. Claeyssens⁴, S. Castet⁵, R. d'Oiron^6,7, C. Negrier⁸, H. Andersson⁹, S. Bergenstråle⁹, C. Gandossi¹⁰, C. Martinez¹⁰

Abstract Number: PB0859

A Generic Recombinant Factor VIIa Is Comparable to the Branded Novoseven in In-vitro and Pharmacokinetic Studies in Primates

M. Iacobelli¹, N. Sadeghi¹, A. Kouta¹, R. Duff², O. Iqbal¹, D. Hoppensteadt¹, W. Jeske¹, J. Walenga¹, J. Fareed¹

Abstract Number: PB1034

A Multicenter Open-label Single Arm Trial to Evaluate Safety and Efficacy and Pharmacokinetics of Recombinant Human Coagulation Factor VIII (SCT800) in Previously Treated Patients with Severe Hemophilia A under Prophylaxis Therapy

W. Liu¹, X. Zhao², F. Xue¹, J. Sun³, X. Zeng⁴, F. Yang⁵, Z. Yu⁶, M. Xu⁷, W. Li⁸, W. Gu⁹, Y. Feng¹⁰, C. Zheng¹¹, H. Bi¹², R. Yang¹

Abstract Number: PB0802

A Multicenter Prospective Validation Study on Disseminated Intravascular Coagulation in Trauma-Induced Coagulopathy

S. Gando¹, A. Shiraishi², T. Wada³, K. Yamakawa⁴, T. Mayumi⁵, Y. Otomo⁶, JAAM Forecast

Abstract Number: PB0799

A New Classification of Sepsis-Associated Disseminated Intravascular Coagulation (DIC) Based on Comprehensive Evaluation of Coagulation and Fibrinolysis

T. Onishi¹, K. Nogami¹, T. Ishihara¹, S. Inoue², M. Kawaguchi², K. Nishio³, H. Fukushima⁴, H. Kobayashi⁵, I. Amano⁶, T. Nishikubo⁷, M. Yamasaki⁸, M. Kasahara⁹, M. Shima¹

Abstract Number: PB1144

A Next Generation Recombinant Factor VIII for Subcutaneous Hemophilia A Prophylaxis

P. Herbener¹, J. Schüttrumpf², J. Daufenbach¹, S. Kistner¹

Abstract Number: LB/CO01.1

A Novel Adeno Associated Virus (AAV) Gene Therapy (FLT180a) Achieves Normal FIX Activity Levels in Severe Hemophilia B (HB) Patients (B-AMAZE Study)

P. Chowdary^1,2, S. Shapiro³, M. Makris⁴, G. Evans⁵, S. Boyce⁶, K. Talks⁷, G. Dolan⁸, U. Reiss⁹, M. Phillips¹, A. Riddell¹, M.R. Peralta¹, M. Quaye², E. Tuddenham¹, J. Krop¹⁰, G. Short¹¹, S. Kar¹¹, A. Smith¹¹, A. Nathwani^1,2

Abstract Number: PB1147

A Novel FVIIIa-Mimetic Bispecific Antibody, Mim8, Enhances FIXa Proteolytic Activity While Allowing for Efficient, Lipid-Dependent Assembly with FX

J. Lund, H. Østergaard, P.J. Greisen, A.C. Bonde, P.S. Gandhi, N. Lorenzen, E. Johansson, L.M. Andersen, M.G. Rasch, S. Lund, R. Zhou, J.R. Bjelke, G. Røder, L.B. Johnsen, F. Stavenuiter, T. Egebjerg, A. Henriksen, B.G. Hansen, K. Thorn, I. Hilden

Abstract Number: PB1097

A Novel Human Factor VIII Variant Exhibits Increased Factor VIII Expression after AAV Gene Therapy in a Unique Hemophilia A Dog Model that is Tolerant to Human Factor VIII

G. Nguyen¹, E. Merricks², T. Long², K. Ponder³, T. Nichols², D. Sabatino^1,4

« View all themes from the ISTH 2020 Congress